SeptiCyte – Sepsis diagnosis technology

Last updated: 28th March, 2024


SeptiCyte® technology can assess a patients dysregulated immune response by quantifying and analysing gene expression signatures from whole blood, providing an accurate sepsis diagnosis and actionable results in about an hour, to guide the physician in optimising patient management decisions.

The dysregulated immune response is the key to unlocking a sepsis diagnosis and initiating sepsis treatment of patients suspected of sepsis. The human immune system responds specifically to an invading pathogen and produces an abundant genetic signal of blood biomarkers that is reliably detected by SeptiCyte technology. Using mathematical algorithms, a patients genetic material from the septic dysregulated immune response is rapidly analysed, providing an actionable sepsis diagnosis in suspected sepsis cases.

Understanding Host Response to Create Better Diagnostic Tools

Determining infection status in suspected sepsis patients has traditionally focused on characterisation and identification of pathogens, for example by microbiological culture.

Detection of an invading pathogen by blood culture is often slow with no identification in the majority of suspected sepsis cases. However, the immune system responds specifically to an invading pathogen and, in the case of sepsis, produces an intense dysregulated immune response that is reliably detected by SeptiCyte technology.

Specific Host Response

How to improve accuracy and accessibility to a fast sepsis test?

SeptiCyte technology does not focus on the identification of pathogens, but rather on the detection of the dysregulated host immune response that is a hallmark of sepsis. SeptiCyte technology utilises this as the key to unlocking a sepsis diagnosis, which in turn can lead to the appropriate initiation of therapeutic treatment of patients suspected of sepsis.

Immune cells contain variable amounts of many specific messenger RNAs which together provide a ‘snapshot’ or profile of the host response to the invading pathogen. Immunexpress algorithmic approach quantifies specific messenger RNAs within the patient’s immune response, and rapidly reports an actionable sepsis diagnosis in 100% of suspected sepsis cases.

Accuracy and Accessibility


SeptiCyte host response results allow clinicians to better interpret positive and negative pathogen results.

Earlier, Faster and More Reliable Than Identification of Pathogens

SeptiCyte RAPID* enables clinicians to swiftly differentiate the systemic inflammatory response syndrome (SIRS) from sepsis in critically ill patients to be admitted to the ICU. SeptiCyte RAPID can detect the response of the patient’s immune system to an infection earlier and faster than other non-specific sepsis markers.


Richard Brandon, Chief Scientific Officer at Immunexpress, on Slice of Healthcare BioBreakthroughs

View the interview >

CLP Magazine, page 13 Why Better Sepsis Diagnosis Results in Better Outcomes

View the article >

Clinical research results published in peer-reviewed medical journals have demonstrated the accuracy of SeptiCyte technology in both adults and children suspected of sepsis

View the research >

*SeptiCyte RAPID is available for IVD use in Australia and New Zealand.

Request a Quote

Request Quote

Go BackGo Back